Adult Dosing

Onychomycosis of the toenails

• Apply SOLN to the affected and surrounding area qd x 48 weeks

Note:

• Clean and dry affected area before use; apply tavaborole to completely cover the toenail surface and under the tip of each toenail being treated

Pediatric Dosing

• Safety and efficacy in pediatric patients have not been established

• Onychomycosis of the toenails due to <i> Trichophyton rubrum </i> or <i>Trichophyton mentagrophytes </i>

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustment not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustment not defined

• Topical use only; not for oral, ophthalmic, or intravaginal use
• Product is flammable; avoid use near heat or open flame
• Inform a health care professional if area of application shows signs of persistent irritation (e.g. redness, itching, swelling)

Pregnancy Category:C

Breastfeeding: Safety Unknown; excretion of tavaborole in human milk following topical use is not known, however, nursing women should be cautious about using tavaborole because many drugs are excreted in human milk.

• DERM: Application site exfoliation, erythema, dermatitis; ingrown toenail

• Oxaborole antifungal; inhibits fungal protein synthesis by inhibiting aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS)
• Metabolism: Unknown; CYP450: Unknown
• Excretion: Excreted in the urine

US Trade Name(s)

• Kerydin

US Availability

Kerydin

• SOLN: 5 %

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Dermatologic

Dermatologic Topical Agents

Antifungals

Infectious Disease

Dermatologic Topical Agents

Ant